Cocrystal Pharma: Small Cap Company With Transformative Merger
- Cocrystal Pharma has focused on developing novel medications for treating human viral diseases, including influenza, norovirus, influenza and Hepatitis C.
- The recent merger with RFS Pharma greatly expands this expertise by including Ray Schinazi. Dr. Schinazi was a founder of Triangle Pharmaceuticals, Idenix and Pharmasset.
- Dr. Schinazi has continued to advance the state of the art for pan-genotypic Hepatitis C therapy.
- The capital structure of the company should be clarified with the release of the upcoming 8-K.
There are no Transcripts on COCP.
We currently have no Breaking News on this stock.
COCP vs. ETF Alternatives
Other News & PR